BG104731A - Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems - Google Patents

Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems

Info

Publication number: BG104731A
Authority: BG; Bulgaria
Prior art keywords: formula; production; heterocyclic ring; ring systems; different heterocyclic
Prior art date: 1999-08-31

Application number

BG104731A

Other languages

Bulgarian (bg)

English (en)

Inventor

Timothy Norris

John Lambert

Megan HNATOW

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-31

Filing date

2000-08-29

Publication date

2001-09-28

2000-08-29 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2001-09-28 Publication of BG104731A publication Critical patent/BG104731A/xx

Links

238000000034 method Methods 0.000 title abstract 4
239000000867 Lipoxygenase Inhibitor Substances 0.000 title 1
125000000623 heterocyclic group Chemical group 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
239000000010 aprotic solvent Substances 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
229910052792 caesium Inorganic materials 0.000 abstract 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 abstract 1
230000006735 deficit Effects 0.000 abstract 1
238000010438 heat treatment Methods 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
229910052744 lithium Inorganic materials 0.000 abstract 1
229910052751 metal Inorganic materials 0.000 abstract 1
239000002184 metal Substances 0.000 abstract 1
239000012299 nitrogen atmosphere Substances 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
229910052700 potassium Inorganic materials 0.000 abstract 1
239000011591 potassium Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
229910052701 rubidium Inorganic materials 0.000 abstract 1
IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1
239000011734 sodium Substances 0.000 abstract 1
125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyrane Compounds (AREA)

BG104731A 1999-08-31 2000-08-29 Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems BG104731A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15161599P	1999-08-31	1999-08-31

Publications (1)

Publication Number	Publication Date
BG104731A true BG104731A (en)	2001-09-28

Family

ID=22539529

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104731A BG104731A (en)	1999-08-31	2000-08-29	Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems

Country Status (33)

Country	Link
US (1)	US6346624B1 (cs)
EP (1)	EP1081143A1 (cs)
JP (1)	JP2001106682A (cs)
KR (1)	KR20010050256A (cs)
CN (1)	CN1286250A (cs)
AP (1)	AP2000001910A0 (cs)
AU (1)	AU5360300A (cs)
BG (1)	BG104731A (cs)
BR (1)	BR0003945A (cs)
CA (1)	CA2317097A1 (cs)
CZ (1)	CZ20003158A3 (cs)
EA (1)	EA200000801A1 (cs)
EE (1)	EE200000512A (cs)
GT (1)	GT200000142A (cs)
HR (1)	HRP20000564A2 (cs)
HU (1)	HUP0003439A3 (cs)
ID (1)	ID27129A (cs)
IL (1)	IL138087A0 (cs)
IS (1)	IS5603A (cs)
MA (1)	MA26751A1 (cs)
NO (1)	NO20004313L (cs)
NZ (1)	NZ506632A (cs)
OA (1)	OA11452A (cs)
PA (1)	PA8499701A1 (cs)
PE (1)	PE20010520A1 (cs)
PL (1)	PL342281A1 (cs)
SG (1)	SG87146A1 (cs)
SK (1)	SK12872000A3 (cs)
SV (1)	SV2002000159A (cs)
TN (1)	TNSN00177A1 (cs)
TR (1)	TR200002529A2 (cs)
UY (1)	UY26314A1 (cs)
ZA (1)	ZA200004435B (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6669042B1 (en) *	2002-09-30	2003-12-30	Hewlett-Packard Development Company, L.P.	Integrated positioning and locking device
US7674811B2 (en)	2006-03-14	2010-03-09	Ranbaxy Laboratories Limited	5-lipoxygenase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5883106A (en) *	1994-10-18	1999-03-16	Pfizer Inc.	5-lipoxygenase inhibitors
SK281577B6 (sk)	1994-10-18	2001-05-10	Pfizer Inc.	Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US6063928A (en) *	1994-10-18	2000-05-16	Pfizer Inc	5-lipoxygenase inhibitors
US6239285B1 (en) *	1998-02-06	2001-05-29	Pfizer Inc	Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems

2000
- 2000-06-29 US US09/607,011 patent/US6346624B1/en not_active Expired - Fee Related
- 2000-08-01 SG SG200004341A patent/SG87146A1/en unknown
- 2000-08-10 PA PA20008499701A patent/PA8499701A1/es unknown
- 2000-08-16 EP EP00307014A patent/EP1081143A1/en not_active Withdrawn
- 2000-08-18 OA OA1200000225A patent/OA11452A/en unknown
- 2000-08-24 AU AU53603/00A patent/AU5360300A/en not_active Abandoned
- 2000-08-24 IL IL13808700A patent/IL138087A0/xx unknown
- 2000-08-25 SK SK1287-2000A patent/SK12872000A3/sk unknown
- 2000-08-25 IS IS5603A patent/IS5603A/is unknown
- 2000-08-28 ID IDP20000711A patent/ID27129A/id unknown
- 2000-08-28 ZA ZA200004435A patent/ZA200004435B/xx unknown
- 2000-08-28 GT GT200000142A patent/GT200000142A/es unknown
- 2000-08-28 UY UY26314A patent/UY26314A1/es not_active Application Discontinuation
- 2000-08-29 JP JP2000259063A patent/JP2001106682A/ja active Pending
- 2000-08-29 PE PE2000000885A patent/PE20010520A1/es not_active Application Discontinuation
- 2000-08-29 BG BG104731A patent/BG104731A/xx unknown
- 2000-08-29 CA CA002317097A patent/CA2317097A1/en not_active Abandoned
- 2000-08-30 NZ NZ506632A patent/NZ506632A/en unknown
- 2000-08-30 HR HR20000564A patent/HRP20000564A2/hr not_active Application Discontinuation
- 2000-08-30 HU HU0003439A patent/HUP0003439A3/hu unknown
- 2000-08-30 KR KR1020000050608A patent/KR20010050256A/ko not_active Abandoned
- 2000-08-30 TN TNTNSN00177A patent/TNSN00177A1/fr unknown
- 2000-08-30 MA MA26054A patent/MA26751A1/fr unknown
- 2000-08-30 NO NO20004313A patent/NO20004313L/no not_active Application Discontinuation
- 2000-08-30 SV SV2000000159A patent/SV2002000159A/es unknown
- 2000-08-30 CN CN00126408A patent/CN1286250A/zh active Pending
- 2000-08-30 CZ CZ20003158A patent/CZ20003158A3/cs unknown
- 2000-08-30 EA EA200000801A patent/EA200000801A1/ru unknown
- 2000-08-31 TR TR2000/02529A patent/TR200002529A2/xx unknown
- 2000-08-31 PL PL00342281A patent/PL342281A1/xx not_active Application Discontinuation
- 2000-08-31 AP APAP/P/2000/001910A patent/AP2000001910A0/en unknown
- 2000-08-31 EE EEP200000512A patent/EE200000512A/xx unknown
- 2000-08-31 BR BR0003945-4A patent/BR0003945A/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
BR0003945A (pt)	2001-04-03
KR20010050256A (ko)	2001-06-15
EE200000512A (et)	2001-04-16
IS5603A (is)	2001-03-01
UY26314A1 (es)	2001-04-30
HUP0003439A3 (en)	2002-08-28
SK12872000A3 (sk)	2001-11-06
NO20004313D0 (no)	2000-08-30
CA2317097A1 (en)	2001-02-28
CN1286250A (zh)	2001-03-07
SG87146A1 (en)	2002-03-19
ZA200004435B (en)	2002-02-28
OA11452A (en)	2003-12-08
PL342281A1 (en)	2001-03-12
TR200002529A2 (tr)	2001-04-20
HUP0003439A2 (hu)	2001-08-28
SV2002000159A (es)	2002-01-23
NZ506632A (en)	2002-02-01
AP2000001910A0 (en)	2000-09-30
TNSN00177A1 (fr)	2005-11-10
CZ20003158A3 (cs)	2001-09-12
EA200000801A1 (ru)	2001-04-23
HU0003439D0 (en)	2000-08-30
HRP20000564A2 (en)	2001-12-31
MA26751A1 (fr)	2004-12-20
PA8499701A1 (es)	2001-12-14
JP2001106682A (ja)	2001-04-17
AU5360300A (en)	2001-03-08
PE20010520A1 (es)	2001-04-28
ID27129A (id)	2001-03-01
NO20004313L (no)	2001-03-01
GT200000142A (es)	2002-02-19
US6346624B1 (en)	2002-02-12
IL138087A0 (en)	2001-10-31
EP1081143A1 (en)	2001-03-07

Publication	Publication Date	Title
AR023152A1 (es)	2002-09-04	Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion
WO2004010515A3 (en)	2004-06-17	Method of synthesizing electrochemically active materials from a slurry of precursors
WO2003082205A3 (en)	2009-04-16	Compounds and methods
NZ248281A (en)	1994-06-27	3-(=ch-oh)benzofuranone; derivatives and preparatory process
NZ504106A (en)	2003-02-28	Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
HUT58692A (en)	1992-03-30	Fungicide, insecticide, arachnicide or nematocide compositions containing o-benzyl-oxime-ethers and process for producing the active components
AU2002211216A1 (en)	2002-04-02	Substituted aminopropoxyaryl derivatives useful as agonists for lxr
HK1053834A1 (zh)	2003-11-07	用作nos抑制劑的n-雜環衍生物
AP1830A (en)	2008-02-22	Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
AU4250200A (en)	2000-11-02	Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
SI1165049T2 (sl)	2011-11-30	Aglomerati s kristalizacijo
WO2003082192A3 (en)	2003-12-18	Certain pharmaceutically useful substituted aminoalkyl heterocycles
GB0019944D0 (en)	2000-09-27	Compositions with vascular damaging activity
BG104731A (en)	2001-09-28	Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems
EP1555261A4 (en)	2007-05-02	VALEROLACTONE COMPOUNDS AND FRAGRANCE COMPOSITION
ZA98780B (en)	1998-07-31	A method for improving the chargeability of a powder coating composition
WO2003031414A1 (en)	2003-04-17	Novel heterocyclic compound and anti-inflammatory agent
IL150120A0 (en)	2002-12-01	Process for the preparation of a pyridinemethanol compound
WO2002072567A3 (en)	2002-11-28	Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
SI1165485T1 (en)	2004-10-31	Processes for preparing pesticidal intermediates
WO2000064882A3 (en)	2001-02-22	Enantiomers of mercapto lactones and processes for their synthesis
EP1132391A4 (en)	2002-06-12	PRODUCTION METHOD FOR 3-SULFONYLOXY-3-CEPHEM COMPOUNDS
IL158145A0 (en)	2004-03-28	Processes for preparing cycloheptapeptide compounds, novel cycloheptapeptide compounds and pharmaceutical compositions containing the same
AU6288700A (en)	2001-01-22	Novel benzo[f]naphthyridine, preparation and compositions containing them
MY103631A (en)	1993-08-28	Certain insecticidal 6-(phenoxy-2-pyridyl)-methyl-neo-phental ethers